Clinical Trials Browser

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05994001 2026-02-18

Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody

Phase 1/2 Active not recruiting

78 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT04005339 2026-01-26

NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

Phase 2 Active not recruiting

48 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gastrointestinal Neoplasms

NCT06591520 2026-01-21

AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer

Phase 3 Active not recruiting

682 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT05036486 2026-01-20

The Registry of Genetic Alterations of Taiwan Biliary Tract Cancer

Active not recruiting

480 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT05170438 2026-01-20

LenPac

Phase 2 Active not recruiting

51 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT06084481 2026-01-20

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

Phase 1 Active not recruiting

302 enrolled

BreastGastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Triple Negative Breast Neoplasms

NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Phase 2 Active not recruiting

217 enrolled 19 charts

BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

NCT02628067 2025-09-22

KEYNOTE 158

Phase 2 Active not recruiting

1,609 enrolled 4 FDA

EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

NCT05297903 2025-09-15

XmAb20717 in Advanced Biliary Tract Cancers

Phase 2 Active not recruiting

27 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT02711553 2025-08-03

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Phase 2 Active not recruiting

309 enrolled 22 charts

Gastrointestinal

Biliary Tract Neoplasms, Neoplasm Metastasis

NCT03478488 2025-05-29

KN035-BTC

Phase 3 Active not recruiting

480 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT03440450 2025-05-18

A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer

Phase 1 Active not recruiting

90 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT06975917 2025-05-16

TOG-SAFRADJU

Active not recruiting

600 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT03695952 2025-01-28

A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors

Active not recruiting

100 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT04308174 2025-01-28

DEBATE

Phase 2 Active not recruiting

45 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04584008 2024-10-15

VISIONARY

Phase NA Active not recruiting

600 enrolled

EndocrineGastrointestinalNETSarcoma

Esophageal Squamous Cell Carcinoma, Biliary Tract Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Unknown Primary, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Gastrointestinal Stromal Tumors

NCT06490107 2024-07-08

Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC

Phase 2 Active not recruiting

40 enrolled

Gastrointestinal

Biliary Tract Neoplasms

Clinical Trials

TOPAZ-1

S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP

A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)

Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers

Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

MINIMUM

TOURMALINE

MTAPESTRY 101

TRAP-BTC

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

PETRA

Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody

NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer

The Registry of Genetic Alterations of Taiwan Biliary Tract Cancer

LenPac

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

KEYNOTE 158

XmAb20717 in Advanced Biliary Tract Cancers

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

KN035-BTC

A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer

TOG-SAFRADJU

A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors

DEBATE

VISIONARY

Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC